JP2021525067A5 - - Google Patents

Info

Publication number
JP2021525067A5
JP2021525067A5 JP2020564146A JP2020564146A JP2021525067A5 JP 2021525067 A5 JP2021525067 A5 JP 2021525067A5 JP 2020564146 A JP2020564146 A JP 2020564146A JP 2020564146 A JP2020564146 A JP 2020564146A JP 2021525067 A5 JP2021525067 A5 JP 2021525067A5
Authority
JP
Japan
Prior art keywords
cell
manipulated
immune cells
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033837 external-priority patent/WO2019226946A1/en
Publication of JP2021525067A publication Critical patent/JP2021525067A/ja
Publication of JP2021525067A5 publication Critical patent/JP2021525067A5/ja
Pending legal-status Critical Current

Links

JP2020564146A 2018-05-23 2019-05-23 T細胞悪性腫瘍の免疫療法のためのキメラ抗原受容体およびcd2の遺伝子編集 Pending JP2021525067A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675525P 2018-05-23 2018-05-23
US62/675,525 2018-05-23
PCT/US2019/033837 WO2019226946A1 (en) 2018-05-23 2019-05-23 Chimeric antigen receptors and gene editing of cd2 for immunotherapy of t-cell malignancies

Publications (2)

Publication Number Publication Date
JP2021525067A JP2021525067A (ja) 2021-09-24
JP2021525067A5 true JP2021525067A5 (cg-RX-API-DMAC7.html) 2022-05-25

Family

ID=68617214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564146A Pending JP2021525067A (ja) 2018-05-23 2019-05-23 T細胞悪性腫瘍の免疫療法のためのキメラ抗原受容体およびcd2の遺伝子編集

Country Status (6)

Country Link
US (1) US20210214439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3784777A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021525067A (cg-RX-API-DMAC7.html)
CN (1) CN112166186A (cg-RX-API-DMAC7.html)
SG (1) SG11202101094TA (cg-RX-API-DMAC7.html)
WO (1) WO2019226946A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7584299B2 (ja) 2018-05-23 2024-11-15 ナショナル ユニバーシティ オブ シンガポール T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現
CA3119296A1 (en) * 2018-11-14 2020-05-22 Medisix Therapeutics Pte Ltd. Two-gene vectors for generating car-t cells and uses thereof
CN113667773A (zh) * 2021-08-19 2021-11-19 南昌艾迪康医学检验实验室有限公司 检测CarT细胞中是否存在RCL污染的引物、探针及试剂盒
WO2024036285A2 (en) * 2022-08-11 2024-02-15 Medisix Therapeutics, Inc. Engineered immune cells expressing a car and a plurality of protein expression blockers and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
EP3294342A4 (en) * 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
US12350349B2 (en) * 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors

Similar Documents

Publication Publication Date Title
AU2022204601B2 (en) Methods for enhancing efficacy of therapeutic immune cells
CN110268049B (zh) 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
Dai et al. Chimeric antigen receptors modified T-cells for cancer therapy
Dougan et al. Immune therapy for cancer
JP2022003043A (ja) 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2023515211A5 (cg-RX-API-DMAC7.html)
JP2019532953A (ja) 増強された有効性を有する免疫エフェクター細胞治療
CA3001859A1 (en) Compositions and methods for inhibition of lineage specific antigens
JP2021525068A5 (cg-RX-API-DMAC7.html)
JP2023500338A5 (cg-RX-API-DMAC7.html)
CN112867498A (zh) 使用嵌合抗原受体基因组编辑和转导t细胞以用于治疗t和b细胞恶性肿瘤的方法
WO2018200713A1 (en) Compositions and methods for targeted tumor immunotherapy
JP2021500878A (ja) 免疫療法のためのt細胞受容体
JP7812549B2 (ja) 人工免疫監視キメラ抗原受容体(ai-car)及びそれを発現する細胞
JP2020536531A (ja) 免疫療法としてのpd1特異的キメラ抗原受容体
JP2025525864A (ja) ナチュラルキラー細胞の機能を増強するための標的遺伝子の遺伝子編集
JP2024540275A5 (cg-RX-API-DMAC7.html)
Danhof et al. CARs and other T cell therapies for MM: the clinical experience
JP2021530971A (ja) 様々な構築物最適化を備えたt細胞抗原カプラ
JP2021501567A (ja) Y182t突然変異を有するt細胞−抗原カプラおよびその方法ならびに使用
KR20240116708A (ko) 자연 살해 세포 및 이의 사용 방법
WO2021084064A1 (en) Sequential anti-cd19 therapy
JP2026501506A (ja) Cldn18.2及びcd3に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
Savani et al. New targets for CAR T therapy in hematologic malignancies
JP2024519614A (ja) Prame特異的t細胞受容体とキメラ補助刺激受容体との組合せ